Company Performance Metrics
Gary Wörtz: Founder & Chief Medical Officer
Rick Ifland: Chief Executive Officer
Cataract surgery is the single most common procedure performed in the United States annually. Despite technological advancements in both surgical instrumentation and intraocular lens design, approximately 50% of patients are still unable to see well without glasses after surgery.
Omega Ophthalmics has developed a new, proprietary lens that will
increase the number of “glasses free” post-surgery patients to over 90% by reducing the variables during surgery, revolutionizing a market that has not seen positive, disruptive change in over sixty years. Since the global intraocular lens market has steadily grown and is currently projected to reach $4.3 billion by 2017, the Omega Gemini Refractive Capsule is well-positioned to become the new standard lens for cataract surgery.
The Omega Gemini Refractive Capsule is an investigational device and is not approved for use in the United States.
